Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Vista sencilla de ítem
dc.creatorRobbiani, Davide F
dc.creatorGaebler, Christian
dc.creatorMuecksch, Frauke
dc.creatorLorenzi, Julio C C
dc.creatorWang, Zijun
dc.creatorCho, Alice
dc.creatorAgudelo, Marianna
dc.creatorBarnes, Christopher O
dc.creatorGazumyan, Anna
dc.creatorFinkin, Shlomo
dc.creatorHägglöf, Thomas
dc.creatorOliveira, Thiago Y
dc.creatorViant, Charlotte
dc.creatorHurley, Arlene
dc.creatorHoffmann, Hans-Heinrich
dc.creatorMillard, Katrina G
dc.creatorKost, Rhonda G
dc.creatorCipolla, Melissa
dc.creatorGordon, Kristie
dc.creatorBianchini, Filippo
dc.creatorChen, Spencer T
dc.creatorRamos, Victor
dc.creatorPatel, Roshni
dc.creatorDizon, Juan
dc.creatorShimeliovich, Irina
dc.creatorMendoza, Pilar
dc.creatorHartweger, Harald
dc.creatorNogueira, Lilian
dc.creatorPack, Maggi
dc.creatorHorowitz, Jill
dc.creatorSchmidt, Fabian
dc.creatorWeisblum, Yiska
dc.creatorMichailidis, Eleftherios
dc.creatorAshbrook, Alison W
dc.creatorWaltari, Eric
dc.creatorPak, John E
dc.creatorHuey-Tubman, Kathryn E
dc.creatorKoranda, Nicholas
dc.creatorHoffman, Pauline R
dc.creatorWest, Anthony P
dc.creatorRice, Charles M
dc.creatorHatziioannou, Theodora
dc.creatorBjorkman, Pamela J
dc.creatorBieniasz, Paul D
dc.creatorCaskey, Marina
dc.creatorNussenzweig, Michel C
dc.date.accessioned2020-07-17T23:04:52Z
dc.date.available2020-07-17T23:04:52Z
dc.date.created2020-06-18
dc.description.abstractenglishDuring the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21–5. Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres: less than 1:50 in 33% and below 1:1,000 in 79%, while only 1% showed titres above 1:5,000. Antibody sequencing revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC50 values) as low as single digit nanograms per millitre. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.spa
dc.format.extent25 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41586-020-2456-9spa
dc.identifier.issn1476-4687spa
dc.identifier.otherhttps://www.nature.com/articles/s41586-020-2456-9spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10819
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectAnticuerpos convergentesspa
dc.subject.keywordConvergent antibody responsesspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleConvergent antibody responses to SARS-CoV-2 in convalescent individualsspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41586-020-2456-9_reference.pdf
Tamaño:
19.73 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19
Cargar más

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS